Press
Releases
Press Releases
Tectonic Therapeutic Appoints Daniel Lochner as Chief Financial Officer
WATERTOWN, Mass.--(BUSINESS WIRE)--Tectonic Therapeutic, Inc. (“Tectonic”), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, today announced the appointment of Daniel Lochner as Chief Financial Officer of Tectonic.
Jun 03, 2024
Tectonic Therapeutic Initiates Phase 1B Study for TX45 in Group 2 Pulmonary Hypertension in Patients with Preserved Ejection Fraction Heart Failure
Study to evaluate TX45 impact on cardiopulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension, a patient population in urgent need of novel therapies TX45 clinical program advancing on track based on promising initial Phase 1A data; confirmatory Phase 1A data expected mid-2024 and
Mar 26, 2024
Tectonic Therapeutic Announces Participation at Investor Conferences in March
Boston, MA (February 27, 2024) – Tectonic Therapeutic, Inc. (“Tectonic”), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, co-founded by Timothy A. Springer and Andrew C. Kruse of Harvard Medical School, today announced that Alise
Feb 27, 2024
AVROBIO and Tectonic Therapeutic Announce Merger
Combined company to be Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Tectonic’s novel GPCR-targeted therapeutic proteins $130.7 million in private financing commitments with new and existing leading life sciences investors in connection with merger Combined company
Jan 30, 2024
Displaying 11 - 14 of 14
Contact Us
Tectonic Therapeutic
490 Arsenal Way, Suite 210
Watertown, MA 02472
info@tectonictx.com
Copyright © 2024 Tectonic Therapeutic | Privacy Notice
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.